Dogwood Therapeutics posts corporate presentation on non-opioid pain, neuropathy drug pipeline

Dogwood

Dogwood

DWTX

0.00
  • Dogwood Therapeutics outlined pipeline focus on non-opioid pain and neuropathy drugs led by Halneuron injection for chemotherapy-induced neuropathic pain (CINP), with Phase 2b data anticipated in 3Q26.
  • Halneuron, a tetrodotoxin-based NaV1.7 sodium channel blocker administered by subcutaneous injection, is being studied in a 4-week Phase 2b trial with final data projected for fall 2026.
  • SP16 IV, which targets LRP1 signaling, has an FDA-accepted IND for chemotherapy-induced peripheral neuropathy, with Phase 1b enrollment expected to start mid-2026.
  • Cash position listed at USD 13.2 million pro forma as of March 31, 2026; shares outstanding 33,629,553.
  • Pipeline history cited acquisition of Halneuron in 4Q24; licensing of SP16 in 4Q25; licensing out of IMC-1/IMC-2 in 2Q26.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.